Nevertheless, given the small number of patients with ALK/EGFR positive NSCLC, it is likely that the worldwide incidence of oligoprogressive disease is significantly greater in the setting of metastatic breast cancer. The gene discussed is ALK; the disease is non-small cell lung carcinoma.